Skip to main content
SpringerLink
Log in

Cardiovascular risk not increased with mirabegron

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. post-authorisation safety study

Reference

  • Hoffman V, et al. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study Drug Safety : 8 Jul 2021. Available from: URL: https://doi.org/10.1007/s40264-021-01095-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cardiovascular risk not increased with mirabegron. Reactions Weekly 1864, 7 (2021). https://doi.org/10.1007/s40278-021-98937-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-98937-6

Search

Navigation